eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2023
vol. 27
 
Share:
Share:
abstract:
Original paper

Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases

Do Mai Linh
1, 2
,
Tran Huy Thinh
3
,
Nguyen-Van Hieu
1
,
Nguyen Minh Duc
4

  1. Department of Oncology, Hanoi Medical University, Hanoi, Vietnam
  2. Department of Medical Oncology 1, Vietnam National Cancer Hospital, Hanoi, Vietnam
  3. Department of Biochemistry, Hanoi Medical University, Hanoi, Vietnam
  4. Department of Radiology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam
Contemp Oncol (Pozn) 2023; 27 (2): 71–79
Online publish date: 2023/07/11
View full text Get citation
 
PlumX metrics:
Introduction:
This study aimed to evaluate the treatment outcomes of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy alone or in combination with locoregional brain therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC) patients with brain metastases.

Material and methods:
A retrospective study involving 72 advanced EGFR-mutant NSCLC patients with brain metastases at the Vietnam National Cancer Hospital were conducted. Patients were divided into 2 groups: EGFR-TKI (erlotinib) monotherapy and EGFR-TKI combined with locoregional therapy (γ knife surgery – GKS or whole-brain radiation therapy). Evaluation criteria included clinical and laboratory characteristics, central nervous system (CNS) progression time, progression-free survival (PFS), overall survival (OS), T790M mutation rate, and adverse events.

Results:
Epidermal growth factor receptor tyrosine kinase inhibitor monotherapy patients had better performance status (PS), fewer CNS symptoms, and significantly fewer brain metastases (p < 0.05). Median PFS and OS were 11 and 25 months, respectively, in both groups. Patients with PS 0–1 had longer median PFS (15 months) than those with PS 2 (7 months) (p = 0.039). Exon 19 deletion patients in both groups had longer median OS (26 months) than those with L858R exon 21 (15 months) (p = 0.023). Patients with T790M mutation who received osimertinib after progression had longer median OS (41 months vs. 23 months, p = 0.0001). Median time to CNS progression was 13.9 months (48 patients). Longer time to CNS progression correlated with longer OS (R2 = 0.89).

Conclusions:
Epidermal growth factor receptor tyrosine kinase inhibitor therapy, with or without locoregional therapy, is effective for advanced EGFR-mutant NSCLC patients with brain metastases. Exon 19 deletion patients had better prognosis.

keywords:

epidermal growth factor receptor, non-small cell lung cancer, brain metastasis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.